Table 2.
Demographics of 97 NSCLC UCLA patients treated on KEYNOTE-001 stratified by history of trAE at any time point. P-values were computed using Fisher’s exact test.
| Characteristic | trAE+ | trAE− | P value | ||
|---|---|---|---|---|---|
| (N=39) | (N=58) | ||||
| Age-year | |||||
| Median | 67 | 65 | |||
| Range | 32 – 78 | 36 – 83 | |||
| Gender - no. (%) | |||||
| Male | 22 | 56% | 28 | 48% | 0.4093 |
| Female | 17 | 44% | 30 | 52% | |
| Previous Therapy Lines - no. (%) | |||||
| 0 | 7 | 18% | 6 | 10% | 0.5967 |
| 1–3 | 23 | 59% | 38 | 66% | |
| ≥3 | 9 | 23% | 14 | 24% | |
| Smoking Status - no. (%) | |||||
| Ever | 24 | 62% | 30 | 52% | 0.4066 |
| Never | 15 | 38% | 28 | 48% | |
| PD-L1 Status - no. (%) | |||||
| Negative | 5 | 13% | 6 | 10% | 0.2116 |
| Positive | 32 | 82% | 42 | 72% | |
| Unknown | 2 | 5% | 10 | 17% | |
| PD-L1 Proportion Score - no. (%) | |||||
| Unknown | 11 | 28% | 10 | 17% | 0.5153 |
| ≤1 | 9 | 23% | 12 | 21% | |
| 1–49 | 14 | 36% | 24 | 41% | |
| ≥50 | 5 | 13% | 12 | 21% | |
| Histology - no. (%) | |||||
| Nonsquamous | 31 | 79% | 47 | 81% | 1 |
| Squamous Cell Carcinoma | 8 | 21% | 11 | 19% | |
| Targetable Mutations - no. (%) | |||||
| EGFR mutation | 9 | 23% | 21 | 36% | 0.1873 |
| ALK Translocation | 0 | 0% | 2 | 3% | 0.5185 |
| Number of AE Occurences per Patient - no. (%) | |||||
| <3 | 1 | 3% | 12 | 21% | <0.0001 |
| 3–7 | 12 | 31% | 32 | 55% | |
| >7 | 26 | 67% | 14 | 24% | |
| Average Number of AE's by Grade per Patient | |||||
| ≥Grade 3 | 1.2 | 1.3 | 0.8614 | ||